CPA
TGTX icon

Capital Performance Advisors’s TG Therapeutics TGTX Stock Holding History

Capital Performance Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23
Closed -$538 – 2433
2024
Q3 		$538 Buy
+23
New +$502 ﹤0.01% 2213

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Performance Advisors's TGTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 23 shares — an estimated $538 sold.

Capital Performance Advisors first reported a position in TGTX in Q3 2024 and held it in 1 quarter. The position peaked at $538 in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 23 TG Therapeutics shares in Q4 2024, an estimated $538.
  • Capital Performance Advisors first reported a position in TG Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's TG Therapeutics position peaked at $538 in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.